- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (indian pharma)
- INDOCO REMEDIES
INDOCO REMEDIES Share Price 
(INDOCO)
Here is the latest stock price and chart of Indoco Remedies. For more details, see the Indoco Remedies company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Sep 18, 2018 (Close) | ||
|---|---|---|---|
| Price (Rs)209.40 | Open (Rs) 213.80 | High (Rs) 215.60 | Low (Rs) 207.00 |
| % Change-1.53 | Volume 6,301 | Value (Rs) 1,330,137 | 52-Week H/L 317.00 / 167.20 |
| Live NSE Quotes | Sep 18, 2018 (Close) | ||
|---|---|---|---|
| Price (Rs)209.80 | Open (Rs) 214.70 | High (Rs) 215.05 | Low (Rs) 207.70 |
| % Change-0.83 | Volume 43,022 | Value (Rs) 9,047,521 | 52-Week H/L 317.40 / 166.00 |
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 5.52 | P/E Ratio (x) 37.92 | Market Cap (Rs m) 19,301.45 | P/BV (x) 2.96 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX
PERIOD - Advanced Charts new
- Charts by TradingView
INDOCO REMEDIES Share Price Today:
INDOCO REMEDIES last traded price was down 1.5% to Rs 209.4 on the BSE. On the NSE, INDOCO REMEDIES last traded price was down 0.8% to Rs 209.8. The total volume of shares traded was 0.0 m.
Overall, the broader S&P BSE HEALTHCARE Index was down by 0.7%. And the benchmark S&P BSE SENSEX was at 37,290.7 (down 0.8%).
Over the last 30 days, the INDOCO REMEDIES share price is up 0.3%. And over the last one year, INDOCO REMEDIES share price is up 5.7%.
|
| |
Today's Market
Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)
After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.
Related Views On News
INDOCO REMEDIES Announces Quarterly Results (4QFY18); Net Profit Up 14.3% (Quarterly Result Update)
Jun 19, 2018 | Updated on Jun 19, 2018For the quarter ended March 2018, INDOCO REMEDIES has posted a net profit of Rs 205 m (up 14.3% YoY). Sales on the other hand came in at Rs 3 bn (down 2.6% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
The Power of 5 Minutes (The 5 Minute Wrapup)
Jun 16, 2017Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
Eris Lifesciences Limited (IPO)
Jun 15, 2017Exposure to high margin specialty products offers promising growth prospects.
More Views on NewsMost Popular
In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)
Sep 6, 2018The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?
As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)
Sep 5, 2018Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?
Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)
Sep 5, 2018The tax collected has gone up a little but the question is at what cost.
The Cream of Small Cap Stocks(Profit Hunter)
Sep 5, 2018Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.
The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)
Sep 7, 2018The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.
MoreTRACK INDOCO REMEDIES
- Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON INDOCO REMEDIES
INDOCO REMEDIES - GEOJIT FINANCIAL SERVICES COMPARISON
COMPARE INDOCO REMEDIES WITH
OTHER USEFUL LINKS
MARKET STATS
|
| |
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.